ClinicalTrials.gg
RecruitingNCT04691622ATLANTICUpdated Jan 26, 2026

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

A Phase 1 interventional study of Norovirus -specific T-cell (NST) therapy in Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT) and Primary Immunodeficiency Disorders (PID), sponsored by Children's National Research Institute. Recruiting at 3 sites in United States. Open to participants aged 3 Months to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Children's National Research Institute · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
3 Months to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 277 studies in Virus Diseases with a site in United States — 34 open to participants now, 50 under way, 5 of them phase 3. Virus Diseases · United States.

Planned enrollment
140th of 231
48 · median 80
Started
2022
with 13 others
Phase 1
83 of 277
7 open now
Primary completion
2028-08
later than 35 of 45 live
Registered
182nd of 277
by date

Among the 277 studies in Virus Diseases with a site in United States, this one is the 140th largest by planned enrollment of the 231 interventional ones that give a count, is one of 14 that started in 2022, is one of 83 in phase 1, reaches primary completion later than 35 of the 45 other live ones, and was the 182nd registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

34 of the 277 studies in Virus Diseases with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 3 Months to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 277 studies in Virus Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are immunocompromised due to PID and have not undergone HSCT, or Solid Organ Transplant (SOT) recipients.

Read the detailed description

This is an open label, phase I study of norovirus-specific T-cell immunotherapy for treatment of participants with primary immunodeficiency disorders (PID) and chronic norovirus. This study is designed to assess the safety of norovirus-specific T-cell (NST) infusion in this population. There are two arms in this study:

  1. Arm A: Participants who receive donor derived NST therapy after HSCT
  2. Arm B: Participants who receive partially HLA matched NSTs. The following participants apply:

    • Participants with PID who have not undergone HSCT.
    • Participants who have undergone HSCT but do not have available donor derived NSTs, or those for whom NSTs cannot be generated due to norovirus seronegativity.
    • Participants who have undergone SOT.

Participants will be monitored for infusion-related reactions and GVHD for 1 year following first infusion. During this time, participants will be accessed with regard to the length and quantity of norovirus shedding in stool, and gastrointestinal and constitutional symptoms will be scored by clinicians and participants. Correlative studies of T-cell immune reconstitution against norovirus, norovirus genomic sequences, and composition of the fecal microbiome will also be accessed.

The primary purpose of this phase I study is to assess the safety of administering donor-derived or partially HLA-matched NSTs in immunocompromised participants with chronic norovirus infections. Related and unrelated donors of participants who have chronic norovirus infection after HSCT will be enrolled for screening and production of NSTs from peripheral blood. Following product manufacturing, participants who have undergone HSCT (Arm A) will receive donor-derived NSTs. For participants with PID who have not undergone HSCT or recipients of SOT (Arm B), high-resolution HLA typing of the participant will be utilized for an inquiry of the NST bank to determine if a partially HLA-matched NST product exists that has antiviral activity mediated through one or more shared HLA alleles. Participants who have undergone HSCT but either do not have available donors for NST generation, or who have donors from whom NSTs cannot be generated due to norovirus seronegativity will also be eligible for inquiry for treatment with partially HLA-matched NSTs if available under study Arm B.

This will be a dose escalation study with two arms. Participants who have undergone HSCT will be enrolled on Arm A and receive NSTs derived from their HSCT donor. Participants with a diagnosis of PID who have not undergone HSCT, recipients of SOT, or participants who have undergone HSCT but do not have available donor-derived NSTs will be enrolled on Arm B and receive partially HLA-matched NSTs. We will test three doses: 1x107 /m2, 2x107 /m2, and 4x107 /m2. Investigators will have a 45-day safety monitoring period for immediate toxicities following infusion.

03

Conditions studied

  • Viral Infection
  • Hematopoietic Stem Cell Transplantation (HSCT)
  • Primary Immunodeficiency Disorders (PID)
04

Who can participate

Ages eligible
3 Months to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participant Inclusion Criteria for NST Infusion:

  1. Participants must meet one of the following criteria:

    1. Recipient of prior myeloablative or non-myeloablative hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood OR
    2. Primary immunodeficiency disorder (as defined by clinical and laboratory evaluations)81 and have not undergone HSCT, OR
    3. Recipients of solid organ transplant.
  2. Documentation of chronic norovirus infection:

    a. Chronic norovirus infections will be defined as having consecutive positive norovirus stool tests (2 or more) spanning a minimum three-month period with attributable signs and symptoms of norovirus disease.

  3. Participants receiving for treatment of or for other reasons, dosage must have been tapered to \<0.5 mg/kg/day of prednisone (or equivalent) a minimum of 7 days prior to infusion.

    a. Treatment with enteral topical steroids such as Budesonide at standard doses may be continued if previously utilized but should not be newly initiated in the 3 months after NST therapy.

  4. For participants who have undergone HSCT, participants must have stable donor chimerism within the 30 days prior to NST infusion.

    a. Stability will be defined as i. >95% donor chimerism in CD33 and/or whole blood chimerism. OR ii. >90% donor chimerism with \<5% change between subsequent tests separated by at least 1 week.

  5. For recipients of solid organ transplants, participants must have stable graft function on maintenance , without evidence of rejection in the past 2 months prior to infusion, as defined by:

    a. Stability of relevant functional testing in the previous 2 months, defined as: i. Renal transplant: renal function ≥ grade 3 per the National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease (2002) ii. Cardiac transplant: maintenance of >40% iii. Lung transplant: lack of baseline oxygen requirement iv. Liver transplant: /ALT ≤3x upper limit normal and ≤2x upper limit normal b. Donor-derived cell free DNA \<2x upper limits for assay in the previous 2 months, c. Stable donor-specific antibody profile in the previous 2 months. i. No increase in antibody titers between most recent testing in the previous 2 months and prior testing.

  6. /Lansky score >50
  7. 3 months to 80 years of age at enrollment.
  8. ≥500/ul.
  9. ≥7.0g/dl (level can be achieved with transfusion).
  10. ≥20 K/ul (level can be achieved with transfusion).
  11. Bilirubin ≤2x upper limit normal.
  12. AST ≤3x upper limit normal.
  13. Serum creatinine ≤2x upper limit normal OR estimated ≥30 ml/hr.
  14. Pulse oximetry of ≥90% on room air.
  15. Negative pregnancy test in female participant of childbearing age.
  16. Written and/or signed assent line from participant, parent or guardian.

Donor Inclusion Criteria:

  1. Donors who have fulfilled eligibility as per United States Food and Drug Administration (FDA) regulations outlined in 21 Code of Federal Regulations (CFR) 1271 subpart C. This includes that donors have been deemed in good health by donor physician based on physical examination and laboratory testing. If a donor has been chosen for the transplant based on urgent medical need, that same donor will also be used for NST generation provided that there are no new reasons for ineligibility since the stem cell collection.
  2. For third-party banking, donors must be between 2 to 35 years of age (females) or 2 to 40 years of age (males).
  3. Donor or guardian of pediatric donor capable of providing informed consent.
  4. Donor (related or unrelated) must have completed Infectious Disease (ID) testing up to 7 days before or after the collection of blood for NST manufacturing. The following tests will be performed:

    • HBc Antibody
    • Antibody
    • 1/2 Antibody
    • HTLV I/II Antibody
    • T. Cruzi Antibody (Chagas)
    • CMV Total Antibody
    • Syphilis (T. Pallidum IgG and IgM)
    • HBV, HCV, HIV Nucleic Acid testing (NAT)
    • WNV NAT
  5. Female donors of childbearing age must have a negative pregnancy test and not be lactating.

Exclusion criteria

Exclusion Criteria:

Participants Exclusion Criteria for NST Infusion:

  1. Participants receiving biological or monoclonal antibodies targeting T cells within 28 days prior to NST infusion, including ATG, Alemtuzumab, Basiliximab, Tocilizumab, Brentuximab, or other medications under this category as determined by the investigators.

    a) If alemtuzumab has been received within 6 weeks prior to NST infusion, plasma levels should be obtained to ensure drug clearance (≤0.16 pg/ml).

  2. Participants who have received donor lymphocyte infusion (DLI), chimeric antigen receptor T cell infusion, or other experimental cellular therapies within 28 days prior to NST infusion.
  3. Participants with SCID who have undergone α/β TCR depleted within the past 100 days post-transplant.
  4. Participants who have received ruxolitinib or other JAK inhibitors within 7 days prior to NST infusion.
  5. Participants with uncontrolled or progressing infections other than norovirus. Uncontrolled infections are defined as bacterial, fungal, or non-targeted viral infections with either clinical signs of worsening despite standard therapy, or chronic gastrointestinal symptoms that may be attributed to the uncontrolled infection. Progressing infection is defined as hemodynamic instability, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.

    1. For bacterial infections, participants must be receiving definitive therapy and have no signs of progressing infection within 7 days prior to NST infusion and or no chronic gastrointestinal symptoms associated with this bacterial infection.
    2. For fungal infections, participants must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection within 7 days prior to NST infusion.
  6. Participants must not have other active gastrointestinal infections to which symptoms may be attributable, including parasitic infections (cryptosporidium, giardiasis), viral infections aside from norovirus (CMV colitis, rotavirus, adenovirus), or bacterial infections with C. difficile, Yersinia, Campylobacter, Salmonella, Shigella, or enteroinvasive or enterotoxigenic E. coli.

    a) Testing for unrelated gastrointestinal (GI) infections must be performed within 14 days prior to NST infusion, and must include: i. Crytosporidium/Giardia testing via antigen or PCR testing. ii. Stool viral testing for rotavirus and adenovirus via antigen or PCR testing.

    iii. Stool bacterial culture or PCR testing. iv. C. difficile toxin PCR. b) Determination of active infection versus chronic carriage/shedding will be made by the investigators and clinical providers and will depend on the presence of clinical symptoms corresponding with the timing of positive test results, presence of a clinical response to targeted therapy, and by histological or other testing if clinically indicated.

  7. Participants with active and uncontrolled relapse of (if applicable).

    1. Failure of primary engraftment is defined as failure to achieve and/or neutrophil engraftment (ANC \<500/ul and/or platelets \<20 K/ul) following HSCT.
    2. Secondary graft failure is defined as \<5% donor chimerism (CD3+ or CD34+) or permanent loss of neutrophil and/or platelet engraftment (ANC \<500/ul and/or platelets \<20 K/ul) at any time after primary engraftment.
  8. Participants with symptomatic gastrointestinal conditions aside from norovirus, including active inflammatory bowel disease or (grades 2 to 4).
  9. Participants who have received a small bowel transplant.
  10. Participants receiving within the previous 3 months prior to NST infusion, including nivolumab, pembrolizumab, or other related medications.
  11. For SOT recipients, alteration in immunosuppression as follows:

    1. Any intensification of immunosuppression (including but not limited to pulse dose or new biologic therapies) in the previous 2 months,
    2. Alteration of maintenance immunosuppression (including changes in the number of agents or dosing goals) in the previous month.
  12. Participants who have received enteral immunoglobulin, nitazoxanide, or other experimental therapies for norovirus infection within 28 days prior to NST infusion.
  13. Co-enrollment in other trials is restricted, other than enrollment on natural history or observational studies. Study staff should be notified of co-enrollment as it may require the approval of the investigator or sponsor.

Donor Exclusion Criteria:

1. Donation of cells would pose a physical or psychological risk to the donor

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Norovirus -specific T-cell (NST) therapy for chronic norovirus infection

    This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or with primary immunodeficiency disorders (PID) who have not undergone HSCT. There are two arms in this study: 1. Arm A: Participants who receive donor-derived NST therapy after HSCT 2. Arm B: Participants who receive partially HLA matched NSTs. The following participants apply: * Participants with PID who have not undergone HSCT. * Participants who have undergone HSCT but do not have available donor derived NSTs, or those for whom NSTs cannot be generated due to norovirus seronegativity. * Participants who have undergone SOT.

    Biological: Norovirus -specific T-cell (NST) therapy

Interventions

  • BiologicalNorovirus -specific T-cell (NST) therapy

    Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion. Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.

06

What researchers measure

Primary outcomes

  1. Incidence of acute GvHD (grade III-IV)

    Number of patients with acute GvHD grades III-IV

    Time frame: Within 45 days of first NSTs infusion

  2. Incidence of infusion related adverse events as per CTCAE common criteria guidelines.

    Number of patients with Grades 3-5 infusion-related adverse events

    Time frame: Within 45 days of first NSTs infusion

  3. Incidence of non-hematological adverse events

    Number of patients with Grades 4-5 non-hematological adverse events related to the NST product within 45 days of the first infusion

    Time frame: Within 45 days of first NSTs infusion

Secondary outcomes

  1. Antiviral activity

    Antiviral activity will determined by measurements in viral loads by RT-PCR from stool samples in comparison to the mean baseline viral load.

    Time frame: Stool viral loads will be evaluated for 12 months following the final NST infusion.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data will be made available via publication. All raw data, methodologies and statistical analyses will also be made available upon publication.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Aug 2028, 77 months after the start.

Of 58 phase 1 interventional studies under Virus Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's planned 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2020
First posted
Dec 31, 2020
StartActual
Mar 17, 2022
Primary completionEst.
Aug 30, 2028
CompletionEst.
Oct 30, 2028
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04691622
Responsible party
Michael Keller (MD, Children's National Research Institute) — Principal investigator
First posted
Dec 31, 2020
Start date
Mar 17, 2022
Primary completion
Aug 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Jan 26, 2026

Study contacts

Michael Keller, MD
Contact
MKeller@childrensnational.org
202-476-5843
Fahmida Hoq, MBBS, MS
Contact
fhoq@childrensnational.org
202-476-3634
Michael Keller, MD
principal investigator · CNH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion